HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received FDA Breakthrough Device Designation for its HeartBeam System as a tool for assessing potential heart attacks at home. The designation, granted within 30 days of the company's request—ahead of the FDA's 60-day statutory review period—recognizes the potential of HeartBeam's 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, regardless of the patient's location.
The FDA's Breakthrough Device Designation provides prioritized review and increased interaction with the agency as HeartBeam advances its heart attack assessment program. Importantly, the designation is a prerequisite for certain expedited Medicare coverage pathways, which could accelerate patient access and reimbursement if the technology gains clearance for this new indication. This regulatory milestone positions HeartBeam to potentially address a critical gap in cardiac care: the ability to quickly and accurately assess heart attacks outside of a hospital setting.
HeartBeam expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment. Currently, the HeartBeam System with 12-lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software was cleared in December 2025. The company holds over 20 issued patents related to technology enablement.
This news matters because heart attacks are a leading cause of death worldwide, and timely intervention is crucial for survival and recovery. HeartBeam's cable-free device, which collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG, could empower patients to assess symptoms at home and connect with physicians for immediate guidance. By redefining cardiac health management outside medical facilities, this technology may reduce delays in treatment, lower healthcare costs, and improve outcomes.
For investors, the FDA designation could signal a faster path to market expansion and potential Medicare coverage, enhancing the company's growth prospects. The global cardiac monitoring market is substantial, and HeartBeam's innovative approach may capture a significant share if the pivotal study succeeds. The company's recent clearances and robust patent portfolio further strengthen its position.
To view the full press release, visit https://nnw.fm/FxKxf. The latest news and updates relating to BEAT are available in the company's newsroom at https://nnw.fm/BEAT. For details on the intended use of its technology, refer to the Company's Cleared Indications for Use at https://www.heartbeam.com/indications.
NetworkNewsWire (NetworkNewsWire) is a specialized communications platform with a focus on financial news and content distribution. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
